Publications by authors named "Carlos Escobar Cervantes"

Claim this Profile
I
Impact of therapeutic inertia in lipid-lowering therapy in patients at very high cardiovascular risk.
Juan Cosín Sales, Carlos Escobar Cervantes, José Javier Gómez-Barrado, José Manuel Andreu Cayuelas, Abel García Del Egido

Clin Investig Arterioscler· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrating New Technologies in Lipidology: A Comprehensive Review.
Carlos Escobar-Cervantes, Jesús Saldaña-García, Ana Torremocha-López, Cristina Contreras-Lorenzo, Alejandro Lara-García

J Clin Med· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
From the Cardiovascular-Kidney-Metabolic Disorders to the Atherosclerotic Cardiovascular Diseases: Their Prevalence Rates and Independent Associations in the SIMETAP Study.
Antonio Ruiz-García, Vicente Pallarés-Carratalá, Adalberto Serrano-Cumplido, Vicente Pascual-Fuster, Ezequiel Arranz-Martínez, Carlos Escobar-Cervantes

J Clin Med· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-Power Short-Duration Radiofrequency Application for Faster and Safer Pulmonary Vein Isolation: The POWER-FAST III Trial.
Sergio Castrejón-Castrejón, Marcel Martínez Cossiani, Nuria Basterra Sola, Javier David Romero Roldán, José Luis Ibáñez Criado, Carlos Escobar Cervantes

JACC Clin Electrophysiol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
From Metabolic Syndrome to Cardio-Kidney-Metabolic Syndrome in the SIMETAP Study: Prevalence Rates of Metabolic Syndrome and Its Independent Associations with Cardio-Renal-Metabolic Disorders Other than Its Defining Criteria.
Antonio Ruiz-García, Ezequiel Arranz-Martínez, Adalberto Serrano-Cumplido, Sergio Cinza-Sanjurjo, Carlos Escobar-Cervantes

Biomedicines· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence Rates of Abdominal Obesity, High Waist-to-Height Ratio and Excess Adiposity, and Their Associated Cardio-Kidney-Metabolic Factors: SIMETAP-AO Study.
Antonio Ruiz-García, Adalberto Serrano-Cumplido, Carlos Escobar-Cervantes, Ezequiel Arranz-Martínez, Vicente Pallarés-Carratalá

Nutrients· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SGLT2 inhibitors and GLP-1 receptor agonists: the definitive combination?
Carlos Escobar Cervantes

Lancet Diabetes Endocrinol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hyperuricaemia Prevalence Rates According to Their Physiochemical and Epidemiological Diagnostic Criteria and Their Associations with Cardio-Renal-Metabolic Factors: SIMETAP-HU Study.
Antonio Ruiz-García, Adalberto Serrano-Cumplido, Ezequiel Arranz-Martínez, Carlos Escobar-Cervantes, Vicente Pallarés-Carratalá

J Clin Med· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atrial Fibrillation Prevalence Rates and Its Association with Cardiovascular-Kidney-Metabolic Factors: SIMETAP-AF Study.
Antonio Ruiz-García, Adalberto Serrano-Cumplido, Carlos Escobar-Cervantes, Ezequiel Arranz-Martínez, Vicente Pallarés-Carratalá

Medicina (Kaunas)· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vascular protection with rivaroxaban in the comprehensive management of atrial fibrillation.
Carlos Escobar-Cervantes, Pablo Díez-Villanueva, Clara Bonanad Lozano, Antonio Pose Reino, Manuel Almendro-Delia

Expert Rev Cardiovasc Ther· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Should atrial fibrillation be considered a vascular disease? The need for a comprehensive vascular approach.
Carlos Escobar-Cervantes, Antonio Pose Reino, Pablo Díez-Villanueva, Lorenzo Facila, Román Freixa-Pamias

Expert Rev Cardiovasc Ther· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical characteristics, treatment, and blood pressure control in patients with hypertension seen by primary care physicians in Spain: the IBERICAN study.
Miguel A Prieto-Díaz, Vicente Pallares-Carratala, Rafael Manuel Micó-Pérez, Carlos Escobar-Cervantes, Vicente Martín-Sanchez

Front Cardiovasc Med· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter prospective comparison of conventional and high-power short duration radiofrequency application for pulmonary vein isolation: the high-power short-duration radiofrequency application for faster and safer pulmonary vein ablation (POWER FAST III) trial.
Sergio Castrejón-Castrejón, Marcel Martínez Cossiani, Miguel Jáuregui-Abularach, Nuria Basterra Sola, José Luis Ibáñez Criado, Carlos Escobar Cervantes

J Interv Card Electrophysiol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypercholesterolaemia control in Spain: The same situation with different regional realities.
Juan Pedro-Botet, Núria Plana, José María Mostaza, Juan José Gómez-Doblas, María Rosa Fernández Olmo, Carlos Escobar Cervantes

Clin Investig Arterioscler· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognosis of Systolic Pressure 130 to 139 According to Risk. A Prospective Cohort Study Between 1992 and 2019.
Juan A Divison-Garrote, Julio A Carbayo-Herencia, Marta Simarro-Rueda, Francisca Molina-Escribano, Carlos Escobar-Cervantes

Hypertension· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence Rates of Arterial Hypertension According to the Threshold Criteria of 140/90 or 130/80 mmHg and Associated Cardiometabolic and Renal Factors: SIMETAP-HTN Study.
Vicente Pallarés-Carratalá, Antonio Ruiz-García, Adalberto Serrano-Cumplido, Ezequiel Arranz-Martínez, Juan Antonio Divisón-Garrote, Carlos Escobar-Cervantes

Medicina (Kaunas)· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Heart Failure Prevalence Rates and Its Association with Other Cardiovascular Diseases and Chronic Kidney Disease: SIMETAP-HF Study.
Antonio Ruiz-García, Adalberto Serrano-Cumplido, Carlos Escobar-Cervantes, Ezequiel Arranz-Martínez, Miguel Turégano-Yedro

J Clin Med· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of physician's perception about LDL cholesterol control in clinical practice when treating patients in Spain.
Juan Cosín-Sales, Raquel Campuzano Ruiz, José Luis Díaz Díaz, Carlos Escobar Cervantes, María Rosa Fernández Olmo

Atherosclerosis· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comprehensive Cardiovascular and Renal Protection in Patients with Type 2 Diabetes.
Almudena Castro Conde, Domingo Marzal Martín, Raquel Campuzano Ruiz, Maria Rosa Fernández Olmo, Carlos Morillas Ariño, Carlos Escobar Cervantes

J Clin Med· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identifying the patient with heart failure to be treated with vericiguat.
Carlos Escobar Cervantes, Alberto Esteban Fernández, Alejandro Recio Mayoral, Sonia Mirabet, José González Costello

Curr Med Res Opin· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benefits of dapagliflozin in the whole spectrum of heart failure in clinical practice: the RICA registry.
Manuel Montero-Pérez-Barquero, Carlos Escobar-Cervantes, Melitón Francisco Dávila-Ramos, Iván Suárez-Pedreira, José Pérez-Silvestre

Future Cardiol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Projected clinical benefits of dapagliflozin in patients with heart failure with preserved ejection fraction.
Manuel Montero-Pérez-Barquero, Carlos Escobar-Cervantes, Pau Llàcer, Raúl Quirós-López, Joan C Trullás

Future Cardiol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Projected effectiveness of dapagliflozin in heart failure with reduced ejection fraction in clinical practice.
Manuel Montero-Pérez-Barquero, Carlos Escobar-Cervantes, José Carlos Arévalo-Lorido, Alicia Conde-Martel, Prado Salamanca-Bautista

Future Cardiol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing the management of patients with worsening heart failure: beyond heart failure hospitalization.
Alberto Esteban Fernández, Alejandro Recio Mayoral, Alvaro González Franco, Julio Núñez Villota, Sonia Mirabet, Carlos Escobar Cervantes

Expert Opin Pharmacother· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral Sodium Chloride in the Prevention of Contrast-Associated Acute Kidney Injury in Elderly Outpatients: The PNIC-Na Randomized Non-Inferiority Trial.
Cecilia Suárez Carantoña, Carlos Escobar Cervantes, Martín Fabregate, Mónica López Rodríguez, Nuria Bara Ledesma

J Clin Med· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis